Ginkgo Bioworks Holdings, Inc.

NYSE•DNA

CEO: Dr. Jason Kelly Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-04-19

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

連絡先情報

27 Drydock Avenue, 8th Floor, Boston, MA, 02210, United States

877-422-5362

www.ginkgobioworks.com

時価総額

$396.32M

PER (TTM)

-1.1

1.4

配当利回り

52週高値

$17.58

52週安値

$5.00

52週レンジ

11%

順位66Top 96.8%

1.5

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 1.5 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$33.40M+0.00%

直近4四半期の推移

EPS

-$1.43+0.00%

直近4四半期の推移

フリーCF

-$63.00M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Operating Expenses Decline Total operating expenses fell $301.3M to $485.4M in 2025; R&D expenses decreased $180.3M reflecting restructuring.

Net Loss Narrows Net loss improved $234.3M to $(312.8)M in 2025, driven by lower operating costs and no goodwill impairment recorded.

Operating Cash Burn Reduced Net cash used in operating activities decreased $148.5M to $(171.1)M in 2025, reflecting successful cost control measures.

Biosecurity Segment Sale Agreed Entered agreement February 2026 to sell Biosecurity Business for approximately 20% equity stake in Tower Biosecurity.

リスク要因

Continued Net Losses Expected Company has history of net losses; expects continued losses for foreseeable future, may never achieve profitability or sustain growth.

Critical Supplier Dependency Risks Reliance on limited, single-source suppliers for critical lab supplies exposes business to supply chain delays and cost risks.

Revenue Concentration Risk Significant revenue concentration exists; one Cell Engineering customer accounted for 15% of total 2025 revenue.

Synthetic Biology Technology Risk Rapidly changing synthetic biology technology risks making current platform, programs, and services obsolete or non-competitive.

見通し

Investing in Tools Offerings Anticipates expenditures exceeding revenue; plans to further invest in and expand proprietary tools offerings and platform capabilities.

Expanding AI/ML Capabilities Continue developing and deploying generative AI and machine learning tools to enhance biological R&D efficiency and throughput.

Need for Future Capital Expects continued net losses, requiring substantial additional capital to fund business development and platform expansion.

Maintain Multi-Class Structure Expects to maintain concentrated voting power via multi-class stock structure to prioritize long-term goals over short-term results.

同業比較

売上高 (TTM)

IOVA

$263.50M

+60.6%

ARVN

$262.60M

-0.3%

VALN

$198.55M

+13.5%

粗利益率 (最新四半期)

VIR

672.1%

-54902.1pp

IOVA

215.9%

+65.9pp

DNA

124.4%

-21.7pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
NRIX	$1.35B	-5.6	-57.5%	8.1%
IOVA	$1.35B	-4.2	-54.5%	5.3%
VIR	$1.32B	-3.0	-49.3%	18.6%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-11.6%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月5日

EPS:-

売上高:$41.50M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし